[Long-time preservation of type red blood cells in the liquid nitrogen].

M. Kout,E. Dobrý,M. Řezníčková,J. Livora

Abstract:

What problem does this paper attempt to address?

A Systematic Review and Meta-Analysis of Serologic Response following Coronavirus Disease 2019 (COVID-19) Vaccination in Solid Organ Transplant Recipients

Atsushi Sakuraba,Alexander Luna,Dejan Micic

DOI: https://doi.org/10.3390/v14081822

2022-08-19

Viruses

Abstract:Solid organ transplant (SOT) recipients are at greater risk of coronavirus disease 2019 (COVID-19) and have attenuated response to vaccinations. In the present meta-analysis, we aimed to evaluate the serologic response to the COVID-19 vaccine in SOT recipients. A search of electronic databases was conducted to identify SOT studies that reported the serologic response to COVID-19 vaccination. We analyzed 44 observational studies including 6158 SOT recipients. Most studies were on mRNA vaccination (mRNA-1273 or BNT162b2). After a single and two doses of vaccine, serologic response rates were 8.6% (95% CI 6.8-11.0) and 34.2% (95% CI 30.1-38.7), respectively. Compared to controls, response rates were lower after a single and two doses of vaccine (OR 0.0049 [95% CI 0.0021-0.012] and 0.0057 [95% CI 0.0030-0.011], respectively). A third dose improved the rate to 65.6% (95% CI 60.4-70.2), but in a subset of patients who had not achieved a response after two doses, it remained low at 35.7% (95% CI 21.2-53.3). In summary, only a small proportion of SOT recipients achieved serologic response to the COVID-19 mRNA vaccine, and that even the third dose had an insufficient response. Alternative strategies for prophylaxis in SOT patients need to be developed. Key Contribution: In this meta-analysis that included 6158 solid organ transplant recipients, the serologic response to the COVID-19 vaccine was extremely low after one (8.6%) and two doses (34.2%). The third dose of the vaccine improved the rate only to 66%, and in the subset of patients who had not achieved a response after two doses, it remained low at 36%. The results of our study suggest that a significant proportion of solid organ transplant recipients are unable to achieve a sufficient serologic response after completing not only the two series of vaccination but also the third booster dose. There is an urgent need to develop strategies for prophylaxis including modified vaccine schedules or the use of monoclonal antibodies in this vulnerable patient population.
Humoral and cellular response of COVID-19 vaccine among solid organ transplant recipients: A systematic review and meta-analysis

Hari Shankar Meshram,Vivek Kute,Hemant Rane,Ruchir Dave,Subho Banerjee,Vineet Mishra,Sanshriti Chauhan

DOI: https://doi.org/10.1111/tid.13926

Abstract:Background: We aimed to analyze the humoral and cellular response to standard and booster (additional doses) COVID-19 vaccination in solid organ transplantation (SOT) and the risk factors involved for an impaired response. Methods: We did a systematic review and meta-analysis of studies published up until January 11, 2022, that reported immunogenicity of COVID-19 vaccine among SOT. The study is registered with PROSPERO, number CRD42022300547. Results: Of the 1527 studies, 112 studies, which involved 15391 SOT and 2844 healthy controls, were included. SOT showed a low humoral response (effect size [ES]: 0.44 [0.40-0.48]) in overall and in control studies (log-Odds-ratio [OR]: -4.46 [-8.10 to -2.35]). The humoral response was highest in liver (ES: 0.67 [0.61-0.74]) followed by heart (ES: 0.45 [0.32-0.59]), kidney (ES: 0.40 [0.36-0.45]), kidney-pancreas (ES: 0.33 [0.13-0.53]), and lung (0.27 [0.17-0.37]). The meta-analysis for standard and booster dose (ES: 0.43 [0.39-0.47] vs. 0.51 [0.43-0.54]) showed a marginal increase of 18% efficacy. SOT with prior infection had higher response (ES: 0.94 [0.92-0.96] vs. ES: 0.40 [0.39-0.41]; p-value < .01). The seroresponse with mRNA-12723 mRNA was highest 0.52 (0.40-0.64). Mycophenolic acid (OR: 1.42 [1.21-1.63]) and Belatacept (OR: 1.89 [1.3-2.49]) had highest risk for nonresponse. SOT had a parallelly decreased cellular response (ES: 0.42 [0.32-0.52]) in overall and control studies (OR: -3.12 [-0.4.12 to -2.13]). Interpretation: Overall, SOT develops a suboptimal response compared to the general population. Immunosuppression including mycophenolic acid, belatacept, and tacrolimus is associated with decreased response. Booster doses increase the immune response, but further upgradation in vaccination strategy for SOT is required.
Immunogenicity of COVID-19 vaccines in solid organ transplant recipients: a systematic review and meta-analysis

Xinpei Chen,De Luo,Bingjie Mei,Juan Du,Xiangdong Liu,Hui Xie,Lin Liu,Song Su,Gang Mai

DOI: https://doi.org/10.1016/j.cmi.2022.12.004

IF: 13.31

2022-12-11

Clinical Microbiology and Infection

Abstract:Background Solid organ transplant (SOT) recipients have increased morbidity and mortality risk from coronavirus disease 2019 (COVID-19). Objectives This study aimed to evaluate the immunogenicity of COVID-19 vaccines in SOT recipients. Data sources Electronic databases were searched for eligible reports published from December 1, 2019 to May 31, 2022. Study eligibility criteria We included reports evaluating the humoral immune response (HIR) or cellular immune response (CIR) rate in SOT recipients after COVID-19 vaccines. Participants SOT recipients who received COVID-19 vaccines. Assessment of risk of bias We used the Newcastle-Ottawa Scale to assess bias in case-control and cohort studies. For the randomized controlled trials, the Jadad Scale was used. Methods of data synthesis We used a random-effects model to calculate the pooled rates of immune response with 95% confidence intervals (CI). We used a risk ratio (RR) with 95% CI for a comparison of immune responses between SOT and healthy controls. Results A total of 91 reports involving 11,886 transplant recipients (lung: 655, heart: 539, liver: 1,946 and kidney: 8,746) and 2,125 healthy controls revealed pooled HIR rates after the 1st, 2nd, and 3rd COVID-19 vaccine doses in SOT recipients were 9.5% (95% CI: 7%-11.9%), 43.6% (95% CI: 39.3%-47.8%) and 55.1% (95% CI: 44.7%-65.6%), respectively. For specific organs, the HIR rates were still low after 1st dose vaccination (lung: 4.4%; kidney: 9.4%; heart: 13.2%; liver: 29.5%) and 2nd dose(lung: 28.4%; kidney: 37.6%; heart: 50.3%; liver: 64.5%). Conclusion A booster vaccination enhances the immunogenicity of COVID-19 vaccines in SOT, however, a significant share of the recipients still has not built a detectable HIR after the 3rd dose. This finding calls for alternative approaches, including the use of monoclonal antibodies. In addition, lung transplant recipients need urgent booster vaccination to improve the immune response.

infectious diseases,microbiology
A tribute to Clement A Fox. Member of the Editoral Board 1966--1973.

W. Cowan

The Journal of Comparative Neurology

Abstract:
Monitored COVID-19 vaccine humoral response in immunocompromised solid organ transplant recipients

Afzal Nikaein,Ashley Chemmalakuzhy,Salman Khan,Judson Hunt,Derek Haumpy,Alok Choudhary,Abraham Pinter,Ayrton Sanchez,Mark Lerman

DOI: https://doi.org/10.1016/j.humimm.2024.110760

IF: 2.211

2024-02-04

Human Immunology

Abstract:The SARS-CoV-2 pandemic has resulted in rapid research and vaccine development to help curtail unchecked transmission. However, these studies cannot be applied as easily among every population, such as immunocompromised individuals. In this study, we observed the humoral response of 70 total heart and renal transplant patients to mRNA SARS-CoV-2 vaccinations to help further understand the effectiveness of vaccination in post-transplant patients following second or booster vaccinations. Antibodies were measured by bead technology to detect IgG, as well as IgG/IgM Rapid Cassette tests for confirmation. Immunocompromised patients had a noticeably lower humoral response than non-immunocompromised populations, with an even lower response among Black patients. Our findings also show for the first time various antibody responses to different motifs of the virus , with the lowest being against the S2 motif. A potential link between the duration of immunosuppression and vaccine response was also observed, where patients on immunosuppressants for longer had a stronger response to vaccination compared to recent transplant patients in our study. In addition, younger transplant recipients had a better humoral response to vaccination, and vaccine effectiveness was disproportionate between races. This finding reinforces the continuation of the guidelines for accelerated vaccination schedules for immunocompromised patients.

immunology
Evaluating the antibody response to SARS-COV-2 vaccination amongst kidney transplant recipients at a single nephrology centre

Chukwuma A. Chukwu,Kassir Mahmood,Safa Elmakki,Julie Gorton,Phillip A. Kalra,Dimitrios Poulikakos,Rachel Middleton

DOI: https://doi.org/10.1371/journal.pone.0265130

IF: 3.7

2022-03-10

PLoS ONE

Abstract:Background and objectives Kidney transplant recipients are highly vulnerable to the serious complications of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infections and thus stand to benefit from vaccination. Therefore, it is necessary to establish the effectiveness of available vaccines as this group of patients was not represented in the randomized trials. Design, setting, participants, & measurements A total of 707 consecutive adult kidney transplant recipients in a single center in the United Kingdom were evaluated. 373 were confirmed to have received two doses of either the BNT162b2 (Pfizer-BioNTech) or AZD1222 (Oxford-AstraZeneca) and subsequently had SARS-COV-2 antibody testing were included in the final analysis. Participants were excluded from the analysis if they had a previous history of SARS-COV-2 infection or were seropositive for SARS-COV-2 antibody pre-vaccination. Multivariate and propensity score analyses were performed to identify the predictors of antibody response to SARS-COV-2 vaccines. The primary outcome was seroconversion rates following two vaccine doses. Results Antibody responders were 56.8% (212/373) and non-responders 43.2% (161/373). Antibody response was associated with greater estimated glomerular filtration (eGFR) rate [odds ratio (OR), for every 10 ml/min/1.73m 2 = 1.40 (1.19–1.66), P<0.001] whereas, non-response was associated with mycophenolic acid immunosuppression [OR, 0.02(0.01–0.11), p<0.001] and increasing age [OR per 10year increase, 0.61(0.48–0.78), p<0.001]. In the propensity-score analysis of four treatment variables (vaccine type, mycophenolic acid, corticosteroid, and triple immunosuppression), only mycophenolic acid was significantly associated with vaccine response [adjusted OR by PSA 0.17 (0.07–0.41): p<0.001]. 22 SARS-COV-2 infections were recorded in our cohort following vaccination. 17(77%) infections, with 3 deaths, occurred in the non-responder group. No death occurred in the responder group. Conclusion Vaccine response in allograft recipients after two doses of SARS-COV-2 vaccine is poor compared to the general population. Maintenance with mycophenolic acid appears to have the strongest negative impact on vaccine response.

multidisciplinary sciences
Serological Response and Clinical Protection of Anti-SARS-CoV-2 Vaccination and the Role of Immunosuppressive Drugs in a Cohort of Kidney Transplant Patients

Pinchera Biagio,Carrano Rosa,Schiano Moriello Nicola,Salemi Fabrizio,Piccione Amerigo,Zumbo Giulia,Scotto Riccardo,Villari Riccardo,Romano Paolo,Spirito Lorenzo,Gentile Ivan,Federico II COVID Team Federico II COVID Team

DOI: https://doi.org/10.3390/v14091951

2022-09-03

Viruses

Abstract:Vaccination against SARS-CoV2 represents a key weapon to prevent COVID-19, but lower response rates to vaccination have frequently been reported in solid organ transplant recipients. The aim of our study was to evaluate the rate of seroconversion to SARS-CoV-2 mRNA vaccines in a cohort of kidney transplant recipients and the potential role of the different immunosuppressive regimens. We conducted an observational retrospective cohort study in kidney transplant patients vaccinated for COVID-19. For each patient, we evaluated IgG anti-S-RBD SARS-CoV-2 titers immediately before the administration of first COVID-19 vaccination dose, 20 days after the first dose and 40 days after the second dose. Moreover, we evaluated the type of immunosuppressive treatment and the incidence of vaccine breakthrough SARS-CoV-2 infection. We enrolled 121 kidney transplant patients vaccinated for COVID-19. At the time of administration of the first vaccine dose, all patients had a negative antibody titer; only 4.1% had positive antibody titers 20 days after the first dose. More than half patients 62 (51%) had protective antibody titers 40 days after the second dose. A total of 18 Solid Organ Transplant Recipients (SOTRs) (14.9%) got a SARS-CoV-2 breakthrough infection during the study period. With regard to immunosuppressive regimen, patients on mycophenolate-based regimen (48.7%) showed the lowest antibody response rates (27.5%) compared to other regimens. Our study confirms that kidney transplant patients show a poor response to two doses of COVID-19 vaccination. Moreover, in our study the use of mycophenolate is significantly associated with a non-response to COVID-19 m-RNA vaccines.

virology
Immune response analysis of solid organ transplantation recipients inoculated with inactivated COVID-19 vaccine: A retrospective analysis

Jiazhi Li,Peihua Cao,Zhenhu Chen,Ruihua Deng,Yu Nie,Feixiong Pang,Xiaomian Liu,Haijia Huang,Jianrong Yang,Kebo Zhong,Yanhua Lai

DOI: https://doi.org/10.1515/med-2024-0980

2024-06-19

Open Medicine

Abstract:This study aimed to evaluate the efficacy and safety of solid organ transplantation recipients inoculated with an inactivated COVID-19 vaccine. We retrospectively analyzed the antibody levels and related adverse events of non-transplantation subjects and solid organ transplant recipients, both pre-transplantation (individuals awaiting organ transplantation) and post-transplantation (individuals who have undergone organ transplantation), who received inactivated COVID-19 vaccines from February 2021 to July 2022. The study included 38 pre-transplantation vaccination group, 129 post-transplantation vaccination group, and 246 non-transplantation group. The antibody titer was assessed monthly within the period of 1–12 months after the last injection. The antibody-positive rate among the three groups were 36.84, 20.30, 61.17% ( P < 0.05). The antibody-positive rates among three groups with one, two doses vaccine were not significantly different ( P > 0.05), but were significantly different after three doses ( P < 0.05). The antibody titers among three groups were significantly different after two doses ( P < 0.05). Adverse reactions occurred in six transplant recipients, which were relieved after treatment, and not in the non-transplantation subjects. Inactivated COVID-19 vaccine is safe and effective for solid organ transplantation recipients, at least two doses of which should be completed before organ transplant surgery.

medicine, general & internal
Predictors of Specific Cellular Immunity Response in Kidney Transplant Recipients after Administration of SARS-CoV-2 Inactivated Vaccine

Lei Zhang,Jiaqing Yang,Changchun Lai,Min Deng,Xuanying Deng,Yan Wang,Qiang Zhou,Yichu Liu,Li Wan,Pingchao Li,Jinhong Zhu,Jiali Fang,Jingcai Hou,Na Li,Xingqiang Lai,Feifei Ma,Ning Li,Guanghui Li,Weiya Kong,Weiting Zhang,Jiale Kang,Jiali Li,Haoyu Chen,Mibu Cao,Liqiang Feng,Zheng Chen,Ling Chen,Tianxing Ji

DOI: https://doi.org/10.2139/ssrn.4098858

2022-01-01

Abstract:Background:The immunogenicity of SARS-CoV-2 vaccines is poor in kidney transplant recipients (KTRs). The factors related to poor immunogenicity to vaccination in KTRs are not well defined.Methods:An observational study was conducted in KTRs and healthy individuals who had received two doses of SARS-CoV-2 inactivated vaccine. IgG antibodies against the receptor-binding domain found in the S1 subunit of the spike protein, and against nucleocapsid protein were measured using enzyme-linked immunosorbent assay. Receptor-binding domain (RBD)-angiotensin-converting enzyme 2 interaction-blocking antibodies were measured using commercial kits. T cell responses against the spike and nucleocapsid proteins were detected using enzyme-linked immunosorbent spot assay.Results:No severe adverse effects were observed in KTRs after first or second dose of SARS-CoV-2 inactivated vaccine. IgG antibodies against the receptor- binding domain, and nucleocapsid protein were not effectively induced in a majority of KTRs after the second dose of inactivated vaccine. Specific T cell immunity response was detectable in 30%˗40% KTRs after the second dose of inactivated vaccine. KTRs who developed specific T cell immunity were more likely to be female, and have lower levels of total bilirubin, unconjugated bilirubin, and blood tacrolimus concentrations. Multivariate logistic regression analysis found that blood unconjugated bilirubin and tacrolimus concentration were significantly negatively associated with SARS-CoV-2 specific T cell immunity response in KTRs.Conclusions:Specific T cell immunity response could be induced in 30%-40% KTRs after two doses of inactivated vaccine. Blood unconjugated bilirubin was negatively associated with specific cellular immunity response in KTRs following vaccination.
Effect of antimetabolite regimen on cellular and humoral immune response to SARS-COV-2 vaccination in solid organ transplant recipients.

Manuela Capone,Anna Vanni,Lorenzo Salvati,Giulia Lamacchia,Alessio Mazzoni,Laura Maggi,Lorenzo Cosmi,Francesco Liotta,Paola Romagnani,Luigi Cirillo,Elisa Buti,Vito Terlizzi,Chiara Azzari,Francesco Citera,Federica Barbati,Gian Maria Rossolini,Silvia Bresci,Beatrice Borchi,Annalisa Cavallo,Jessica Mencarini,Emanuela Francalanci,Seble Tekle Kiros,Alessandro Bartoloni,Francesco Annunziato

DOI: https://doi.org/10.1016/j.imlet.2024.106886

IF: 4.23

2024-06-21

Immunology Letters

Abstract:Objective Novel mRNA-based vaccines have been proven to be powerful tools in combating the global pandemic caused by SARS-CoV-2 protecting individuals, especially the immunocompromised, from COVID-19. Still, it remains largely unknown how solid organ transplant and different immunosuppressive medications affect development of vaccine-induced immunity. Methods In this work, we monitored humoral and cellular memory responses after mRNA SARS-CoV-2 two-doses and booster doses vaccination in cystic fibrosis lung transplanted patients (CFT) and compared them with both cystic fibrosis patients without lung transplant (CF) and with kidney transplant recipients (KT). In particular, we investigated the effects of immunosuppressive regimens on immune memory to SARS-CoV-2 after mRNA SARS-CoV-2 vaccine in transplanted patients. Results Our results showed that immunocompromised transplanted patients displayed a weak cellular and humoral memory to SARS-CoV-2 mRNA vaccination. In addition, obtained data clearly demonstrate that immunosuppressive therapy regimen including antimetabolites, further reduces patients' ability to respond to vaccination at both humoral and cell-mediated level. Notably, patient treated with antimetabolites showed a lower humoral and cellular response also after a booster dose vaccination. Conclusion These results, even if obtained on a small patient's cohort, question whether immunocompromised patients need interventions to improve vaccine SARS-CoV-2 mRNA vaccine response such as additional jab or modulation of immunosuppressive therapy.

immunology
Delayed peak antibody titers after the second dose of SARS-CoV-2 vaccine in solid organ transplant recipients: Prospective cohort study

Kohei Unagami,Mikiko Yoshikawa,Hiroto Egawa,Satoko Ohfuji,Yoichiro Natori,Rikako Oki,Tomomi Mori,Hidetoshi Hattori,Ayumi Ishiwatari,Taichi Kanzawa,Tomokazu Shimizu,Kazuya Omoto,Masashi Inui,Yuuki Masano,Takashi Ito,Daisuke Nakajima,Tetsuya Babazono,Toshio Takagi,Shinichi Nunoda,Yoshito Tomimaru,Ryoichi Imamura,Shigeru Miyagawa,Koichi Toda,Etsuro Hatano,Hiroshi Date,Miyaji Kyakuno,Shiro Takahara,Kenji Yuzawa,Naoki Tanimine,Hideki Ohdan,Hideki Ishida,Yoshio Hirota,Japan Solid Organ Transplantation COVID-19 Countermeasure Group

DOI: https://doi.org/10.1016/j.vaccine.2024.126221

IF: 4.169

2024-08-23

Vaccine

Abstract:Poor post-vaccination production of antibody against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a concern among solid organ transplant (SOT) recipients. Furthermore, the timing and kinetics of antibody titers after the second vaccine dose are unknown. We conducted a multicenter prospective observational study that included 614 SOT recipients: 460 kidney, 53 heart, 50 liver, 20 lung, and 31 simultaneous pancreas-kidney (SPK). The participants received two doses of the mRNA vaccine (Pfizer BNT162b2 or Moderna mRNA-1273), as indicated. Serum samples were collected before the first and second vaccinations and at 1, 3, and 6 months after the second vaccine dose, which were then assessed for SARS-CoV-2 antibodies. The overall seropositivity rate was 43% at 1 month after administration of the second vaccine dose; it gradually increased to 68% at 3 months after second dose administration and to 70% at 6 months. In addition, recipient of kidney, lung or SPK transplants had lower antibody titers at the 3- and 6-month time points than did the other recipients. SOT recipients acquired SARS-CoV-2 S-IgG antibodies slowly, and the peak titer differed significantly from that of the general population.
Systems vaccinology identifies clinical and immunological correlates of SARS-CoV-2 vaccine response in solid-organ transplant recipients

Nicolas Gemander,Julika Neumann,Rafael Veiga,Isabelle Etienne,Teresa Prezzemolo,Delphine Kemlin,Pieter Pannus,Stéphanie Depickère,Véronique Olislagers,Inès Vu Duc,Alexandra Waegemans,Margaux Gerbaux,Leoni Bücken,Hafid Dahma,Charlotte Martin,Nicolas Dauby,Maria E Goossens,Isabelle Desombere,Carlos P Roca,Mathijs Willemsen,Stanislas Goriely,Alain Le Moine,Arnaud Marchant,Adrian Liston,Stephanie Humblet-Baron

DOI: https://doi.org/10.1101/2024.04.05.24305357

2024-04-06

Abstract:Solid organ transplant (SOT) recipients are at enhanced risk of adverse outcomes following infectious challenges due to immunosuppressive treatment and additional comorbidities. Unfortunately, SOT recipients are also poor responders to the key medical intervention to preventing infection: vaccines. Here we performed a systems vaccinology study on a cohort of 59 kidney transplant recipients and 31 lung transplant recipients who received the mRNA Pfizer-BioNTech COVID-19 vaccine. Analyzing the immunological status of the patients prior to vaccination, we were able to identify multiple immunological associates of relatively improved vaccine responses following two or three doses of mRNA-based SARS-CoV-2 vaccine. These immunological associates predicted, with 95.0% and 93.3% accuracy, vaccine response after the second and third dose, respectively. Comparison of the immunological associates with vaccine response in SOT recipients revealed two distinct immune configurations: a non-classical configuration, distinct from the immune state of healthy subjects, associated with responses to two doses of mRNA vaccine and that could be mediated partly by the presence of double negative B cell subsets which are more prominently represented in responsive SOT recipients, and a “normalized” configuration, closer to the immune state of healthy subjects, associated with potent antibody responses to three doses of mRNA vaccine. These results suggest that immunosuppression in SOT recipients can result in distinct immune states associated with different trade-offs in vaccine responsiveness. Immune phenotyping of SOT recipients for immune constellation may be an effective approach for identifying patients most at risk of poor vaccine responses and susceptibility to vaccine-preventable diseases.

Allergy and Immunology
Clinical application of COVID-19 vaccine in liver transplant recipients

Feng-Chao Liu,Man Xie,Wei Rao

DOI: https://doi.org/10.1016/j.hbpd.2023.08.010

2023-08-14

Abstract:Background Solid organ transplant (SOT) activities, such as liver transplant, have been greatly influenced by the pandemic of coronavirus disease 2019 (COVID-19), a disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Immunosuppressed individuals of liver transplant recipients (LTRs) tend to have a high risk of COVID-19 infection and related complications. Therefore, COVID-19 vaccination has been recommended to be administered as early as possible in LTRs. Data sources The keywords "liver transplant", "SARS-CoV-2", and "vaccine" were used to retrieve articles published in PubMed. Results The antibody response following the 1st and 2nd doses of vaccination was disappointingly low, and the immune responses among LTRs remarkably improved after the 3rd or 4th dose of vaccination. Although the 3rd or 4th dose of COVID-19 vaccine increased the antibody titer, a proportion of patients remained unresponsive. Furthermore, recent studies showed that SARS-CoV-2 vaccine could trigger adverse events in LTRs, including allograft rejection and liver injury. Conclusions This review provides the recently reported data on the antibody response of LTRs following various doses of vaccine, risk factors for poor serological response and adverse events after vaccination.

gastroenterology & hepatology
Risk factors for SARS-CoV-2 infection and severe COVID-19 in unvaccinated solid organ transplant recipients

Casper Vrij,Kris Bogaerts,Pieter Vermeersch,Katrien Lagrou,Geert Molenberghs,Filip Rega,Laurens J. Ceulemans,Dirk Van Raemdonck,Ina Jochmans,Diethard Monbaliu,Jacques Pirenne,Geert Robaeys,Bart De Moor,Tim Vanuytsel,Pieter Gillard,Hélène Schoemans,Johan Van Cleemput,Dirk Kuypers,Robin Vos,Frederik Nevens,Jef Verbeek

DOI: https://doi.org/10.1038/s41598-024-78119-6

IF: 4.6

2024-11-03

Scientific Reports

Abstract:The role of immunosuppressive therapy on SARS-CoV-2 infection risk and COVID-19 severity remains unclear in unvaccinated solid organ transplant recipients. We included 1957 organ transplant recipients between July 2020 and April 2021 to analyze whether baseline immunosuppressive therapy and other risk factors are associated with SARS-CoV-2 infection and severe COVID-19. In total, 247 (12.6%) had SARS-CoV-2 (defined as positive nasopharyngeal swab and/or positive antibody titer). Of these, 57 (23.1%) had severe COVID-19, defined as oxygen supplementation, intensive care unit admission or death. Multivariable analysis identified diabetes (hazard ratio (HR) 1.39 (95% confidence interval (CI) 1.05–1.83)), chronic lung disease (HR 1.71 (95% CI 1.13–2.60)) and contact with a COVID-19 positive individual (HR 3.61 (95% CI 2.61–4.99) as independent risk factors for SARS-CoV-2 infection. There was no association between immunosuppressive therapy and infection risk. Severe COVID-19 was multivariably associated with hypertension (OR 5.45 (95% CI 1.66–17.84)), chronic kidney disease (OR 3.55 (95% CI 1.75–7.19)), corticosteroid use (OR 2.93 (95% CI 1.03–2.55)) and having a COVID-19 positive housemate (OR 6.77 (95% CI 2.65–17.28)). In conclusion, baseline corticosteroid use, but no other immunosuppressive agent, is independently associated with severe COVID-19 in unvaccinated SOT recipients after correction for hypertension, chronic kidney disease, housemates affected by COVID-19 and transplant type.

multidisciplinary sciences
Prior SARS-CoV2 infection in vaccinated solid organ transplant recipients induces potent neutralization responses against variants, including Omicron

Alok Choudhary,Mark Lerman,David Calianese,Salman Khan,Judson Hunt,Afzal Nikaein,William Honnen,Dabbu Kumar Jaijyan,Erica Kalu,Abraham Pinter

DOI: https://doi.org/10.1101/2022.02.10.22270607

2022-02-15

Abstract:Abstract Factors affecting functional antibody responses in solid organ transplant recipients (SOTRs) to current SARS-CoV2 vaccines are not well understood. Here, we measured vaccine-induced neutralizing activities against the D614G-CoV2 baseline virus and eight variants, including Omicron, in a panel of CoV2 infected- (n=13) and uninfected- (n=63) vaccinated kidney and heart transplant recipients. In the CoV2 uninfected-vaccinated subset, only 19% and 35% of two and three-dose vaccinated recipients respectively possessed minimally protective neutralizing plasma antibody titers (IC50>1:50) against D614G. In contrast, all of the CoV2 infected-vaccinated SOTRs who received two vaccine doses possessed titers exceeding minimal protection; 12/13 exhibiting strong protection (IC50>1:600) against D614G with minimal increases provided by a third dose. Omicron was the most resistant variant: only 10% of CoV2 uninfected-vaccinated SOTRs reached the minimally protective neutralization titer, while 76% of CoV2 infected-vaccinated SOTRs exceeded this value. These results indicate that prior infection and vaccination can induce highly protective antibody responses in many SOTRs, and identify important factors (shorter time since transplantation, prednisone administration, and African American ethnicity) that limit these responses. Overall, these results suggest factors to consider in establishing optimum COVID-19 vaccination strategies in these cohorts.
Optimizing SARS-CoV-2 vaccine responses in kidney transplant recipients: an urgent need

Yi-Ling Cheng,Shen-Shin Chang,Chiao-Hsuan Chao,Po-Ta Chen,Ya-Lan Lin,Guan-Da Syu,Nan-Yao Lee,Po-Lin Chen,Wen-Chien Ko,Tzong-Shiann Ho

DOI: https://doi.org/10.1128/spectrum.00004-24

2024-06-04

Abstract:Kidney transplant recipients (KTRs) have been identified as a population at increased risk for severe SARS-CoV-2 infection outcomes. This study focused on understanding the immune response of KTRs post-vaccination, specifically examining both serological and cellular responses to the SARS-CoV-2 vaccine. Thirteen individuals, including seven KTRs and six healthy donors, were evaluated for antibody levels and T cell responses post-vaccination. The study revealed that KTRs had significantly lower serological responses, including reduced anti-receptor binding domain (RBD) binding antibodies and neutralizing antibodies against the Wuhan, Delta, and Omicron BA.2 strains. Additionally, KTRs demonstrated weaker CD8 T cell cytotoxic responses and lower Th1 cytokine secretion, particularly IFN-γ, after stimulation with variant spike peptide pools. These findings highlight the compromised immunity in KTRs post-vaccination and underscore the need for tailored strategies to bolster immune responses in this vulnerable group. Further investigations are warranted into the mechanisms underlying reduced vaccine efficacy in KTRs and potential therapeutic interventions. Importance: Some studies have revealed that KTRs had lower serological response against SARS-CoV-2 than healthy people. Nevertheless, limited studies investigate the cellular response against SARS-CoV-2 in KTRs receiving SARS-CoV-2 vaccines. Here, we found that KTRs have lower serological and cellular responses. Moreover, we found that KTRs had a significantly lower IFN-γ secretion than healthy individuals when their PBMCs were stimulated with SARS-CoV-2 spike peptide pools. Thus, our findings suggested that additional strategies are needed to enhance KTR immunity triggered by the vaccine.
SARS-CoV-2 vaccine antibody response and breakthrough infections in transplant recipients

Benedict Vanlerberghe,Casper Vrij,Kris Bogaerts,Pieter Vermeersch,Katrien Lagrou,Geert Molenberghs,Filip Rega,Laurens J Ceulemans,Dirk van Raemdonck,Ina Jochmans,Diethard Monbaliu,Jacques Pirenne,Tim Vanuytsel,Pieter Gillard,Hélène Schoemans,Johan Van Cleemput,Dirk Kuypers,Robin Vos,Frederik Nevens,Jef Verbeek

DOI: https://doi.org/10.1002/jmv.28736

Abstract:Rates and modulators of SARS-CoV-2 vaccine nonresponse and breakthrough infections remain unclear in serially vaccinated transplant recipients. In a prospective, mono-centric, observational study, 1878 adult solid organ and hematopoietic cell transplant recipients, with prior SARS-CoV-2 vaccination, were included between March 2021 and February 2022. SARS-CoV-2 anti-spike IgG antibodies were measured at inclusion and details on SARS-CoV-2 vaccine doses and infection were collected. No life-threatening adverse events were reported after a total of 4039 vaccine doses. In transplant recipients without prior SARS-CoV-2 infection (n = 1636), antibody response rates ranged widely, from 47% in lung transplant to 90% in liver transplant and 91% in hematopoietic cell transplant recipients after third vaccine dose. Antibody positivity rate and levels increased after each vaccine dose in all types of transplant recipients. In multivariable analysis, older age, chronic kidney disease and daily dose of mycophenolate and corticosteroids were negatively associated with antibody response rate. Overall rate of breakthrough infections was 25.2% and mainly (90.2%) occurred after third and fourth vaccine dose. Lung transplant recipients had the highest rates of severe breakthrough infection (10.5%) and death (2.5%). In multivariable analysis, older age, daily dose of mycophenolate and corticosteroids were associated with severe breakthrough infection. Transplant recipients with infection before first vaccine dose (n = 160) had higher antibody response rates and levels after each vaccine dose, and a significantly lower overall rate of breakthrough infections compared to those without prior infection. Antibody response after SARS-CoV-2 vaccination and rate of severe breakthrough infections vary largely between different transplant types and are modulated by specific risk factors. The observed heterogeneity supports a tailored approach against COVID-19 in transplant recipients.
Immunogenicity of SARS-CoV-2 mRNA vaccine in dialysis and kidney transplant patients: A systematic review

Merve Akyol,Enes Çevik,Duygu Ucku,Cem Tanrıöver,Barış Afşar,Asiye Kanbay,Adrian Covic,Alberto Ortiz,Carlo Basile,Mehmet Kanbay

DOI: https://doi.org/10.5578/tt.20219612

Tuberk Toraks

Abstract:Kidney transplant recipients and dialysis patients constitute a risk group for severe COVID-19. They are highly advised to get vaccinated according to the current guidelines. However, data on antibody response, cell responses and protection from events, and factors that might alter this response after a routine full series of vaccination remain incomplete for these populations. The aim of this article was to analyze the antibody responses after a full series of mRNA-based SARS-CoV-2 vaccination in kidney transplantation and dialysis patients and to define the factors that alter seroconversion status in these populations. In this systematic review, 18 studies investigating the antibody response to full vaccination with two doses of COVID-19 mRNA vaccines in hemodialysis, peritoneal dialysis, and kidney transplant patients were included. Kidney transplant and dialysis patients have a lower seroconversion rate after mRNA-based SARS-CoV-2 vaccination than the healthy population: 27.2% for kidney transplantation, 88.5% for dialysis patients while all healthy control in these studies seroconverted. Moreover, anti-S antibody titers were lower in seroconverted kidney transplantation or dialysis patients than in healthy control in all studies that assessed this variable. Older age and dialysis vintage, immunosuppressive or chemotherapy treatment, and lower serum albumin, white blood cell, lymphocyte and hemoglobin counts were associated with lower/no antibody response to vaccination. Dialysis patients and kidney transplant recipients have lower seroconversion rates after a full series of mRNA-based SARS-CoV-2 vaccination than the general population. Several factors are associated with an altered antibody response. A third dose could be considered in this patient group.
Risk of Severe COVID-19 and Protective Effectiveness of Vaccination Among Solid Organ Transplant Recipients

Kyungmin Huh,Minsun Kang,Young-Eun Kim,Yoonkyung Choi,Soo Jeong An,Jaehyun Seong,Min Jin Go,Ji-Man Kang,Jaehun Jung

DOI: https://doi.org/10.1093/infdis/jiad501

2024-04-12

Abstract:Background: Solid organ transplant recipients (SOTRs) are at higher risk for severe infection. However, the risk for severe COVID-19 and vaccine effectiveness among SOTRs remain unclear. Methods: This retrospective study used a nationwide health care claims database and COVID-19 registry from the Republic of Korea (2020 to 2022). Adult SOTRs diagnosed with COVID-19 were matched with up to 4 non-SOTR COVID-19 patients by propensity score. Severe COVID-19 was defined as treatment with high-flow nasal cannulae, mechanical ventilation, or extracorporeal membrane oxygenation. Results: Among 6783 SOTRs with COVID-19, severe COVID-19 was reported with the highest rate in lung transplant recipients (13.16%), followed by the heart (6.30%), kidney (3.90%), and liver (2.40%). SOTRs had a higher risk of severe COVID-19 compared to non-SOTRs, and lung transplant recipients showed the highest risk (adjusted odds ratio, 18.14; 95% confidence interval [CI], 8.53-38.58). Vaccine effectiveness against severe disease among SOTRs was 47% (95% CI, 18%-65%), 64% (95% CI, 49%-75%), and 64% (95% CI, 29%-81%) for 2, 3, and 4 doses, respectively. Conclusions: SOTRs are at significantly higher risk for severe COVID-19 compared to non-SOTRs. Vaccination is effective in preventing the progression to severe COVID-19. Efforts should be made to improve vaccine uptake among SOTRs, while additional protective measures should be developed.
SARS-CoV-2 vaccination in liver transplant recipients: factors affecting immune response and refusal to vaccine

Joanna Raszeja-Wyszomirska,Maciej Wójcicki,Piotr Milkiewicz,Maciej K. Janik

DOI: https://doi.org/10.20452/pamw.16274

2022-06-07

Polish Archives of Internal Medicine

Abstract:INTRODUCTION: The effectiveness of SARS‑CoV‑2 vaccination in liver transplant (LT) recipients varies between reports.OBJECTIVES: In this study, we analyzed the immune response to the SARS‑CoV‑2 vaccine, factors affecting the response, and reasons for the vaccine refusal.PATIENTS AND METHODS: Among 300 consecutive LT recipients, 75% were vaccinated. The humoralresponse was assessed by the quantitative determination of antitrimeric spike protein‑specific IgG antibodies to SARS‑CoV‑2. Thirty‑four vaccinated patients with prior SARS‑CoV‑2 infection were analyzed separately.RESULTS: Among 192 LT recipients vaccinated without past natural infection, 69% developed the immune response (median time of 125 days after the second dose). Older age, worse kidney function, and dual immunosuppression negatively affected the humoral response. Mycophenolate mofetil increased the risk of nonresponse (odds ratio [OR], 2.99; 95% CI, 1.45-6.19). The antibody concentration was higher in the first 90 days from the second dose and stable as compared with 90-150 days and over 150 days. LT recipients with prior COVID‑19 presented with a robust immune response (100%). The female sex, living in a rural area, lower body mass index, and younger age (all P <0.05) were associated with the refusal of the vaccine.CONCLUSIONS: The lower immune response in the vaccinated LT recipients than in the general population justifies administering the third dose of the vaccine. However, more data are needed to recommend any therapy modification before the vaccination.

medicine, general & internal

[Long-time preservation of type red blood cells in the liquid nitrogen].

A Systematic Review and Meta-Analysis of Serologic Response following Coronavirus Disease 2019 (COVID-19) Vaccination in Solid Organ Transplant Recipients

Humoral and cellular response of COVID-19 vaccine among solid organ transplant recipients: A systematic review and meta-analysis

Immunogenicity of COVID-19 vaccines in solid organ transplant recipients: a systematic review and meta-analysis

A tribute to Clement A Fox. Member of the Editoral Board 1966--1973.

Monitored COVID-19 vaccine humoral response in immunocompromised solid organ transplant recipients

Evaluating the antibody response to SARS-COV-2 vaccination amongst kidney transplant recipients at a single nephrology centre

Serological Response and Clinical Protection of Anti-SARS-CoV-2 Vaccination and the Role of Immunosuppressive Drugs in a Cohort of Kidney Transplant Patients

Immune response analysis of solid organ transplantation recipients inoculated with inactivated COVID-19 vaccine: A retrospective analysis

Predictors of Specific Cellular Immunity Response in Kidney Transplant Recipients after Administration of SARS-CoV-2 Inactivated Vaccine

Effect of antimetabolite regimen on cellular and humoral immune response to SARS-COV-2 vaccination in solid organ transplant recipients.

Delayed peak antibody titers after the second dose of SARS-CoV-2 vaccine in solid organ transplant recipients: Prospective cohort study

Systems vaccinology identifies clinical and immunological correlates of SARS-CoV-2 vaccine response in solid-organ transplant recipients

Clinical application of COVID-19 vaccine in liver transplant recipients

Risk factors for SARS-CoV-2 infection and severe COVID-19 in unvaccinated solid organ transplant recipients

Prior SARS-CoV2 infection in vaccinated solid organ transplant recipients induces potent neutralization responses against variants, including Omicron

Optimizing SARS-CoV-2 vaccine responses in kidney transplant recipients: an urgent need

SARS-CoV-2 vaccine antibody response and breakthrough infections in transplant recipients

Immunogenicity of SARS-CoV-2 mRNA vaccine in dialysis and kidney transplant patients: A systematic review

Risk of Severe COVID-19 and Protective Effectiveness of Vaccination Among Solid Organ Transplant Recipients

SARS-CoV-2 vaccination in liver transplant recipients: factors affecting immune response and refusal to vaccine